The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Europe Veterinary oncology Market would witness market growth of 12.8% CAGR during the forecast period (2020-2026).
Growing support for the advancement of veterinary oncology treatment is thus expected to improve pet oncology research and thereby promote market growth. In addition, because of the involvement of regulatory authorities based on scientific advancement in veterinary and comparative oncology, the European market is projected to be the second-largest field in terms of revenues. These authorities partner with major industry leaders to focus on delivering unparalleled pet oncology treatment solutions.
Cancer is prevalent in dogs and in recent years, chemotherapy has progressed dramatically with canine oncology becoming a practice in many countries like the UK. However, there were no large-scale trials of the potential side effects of chemotherapeutic drugs in associated animals and very little debate on the ethics of using chemotherapy in these species. In general, the prognosis for animals suffering from malignant neoplasia (which can be conducive to chemotherapy) remains low, and the role of oncology in veterinary medicine can be debated.
The diversity of advanced veterinary oncology treatments both on the market and on the horizon makes it difficult to keep up-to-date on the newest developments and innovations, but this research is important for practices that are involved in offering the best therapeutic options for cancer. Immunotherapy leads the way in the advancement of treatment for human oncology and this pattern continues in veterinary oncology.
Growing cancer pervasiveness in the pet population and increasing the adoption of veterinary cancer therapy as a means of treatment accelerate market growth. Increasing animal healthcare spending in developing economies as a result of increased desire to invest in pet welfare by owners and government initiatives for veterinary cancer treatment are the main drivers of market growth.
Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.
Scope of the Study
By Animal Type
- Canine and
- Immunotherapy and
By Cancer Type
- Mast Cell Cancer
- Mammary & Squamous Cell Cancer and
- Rest of Europe
- Boehringer Ingelheim International GmbH
- Karyopharm Therapeutics, Inc.
- Regeneus Ltd.
- Elanco Animal Health, Inc.
- Zoetis, Inc.
- Varian Medical Systems, Inc.
- PetCure Oncology, LLC (Accelitech, LLC)
- AB Science SA
- Rhizen Pharmaceuticals S.A.
- Nippon Zenyaku Kogyo Co., Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free